September 30, 2025 — Gilead’s Epclusa (sofosbuvir/velpatasvir, 400mg/100mg) continues to reshape hepatitis C management worldwide. As the first and only all-oral, pan-genotypi...
This page summarizes the latest approvals issued by the U.S. Food and Drug Administration (FDA). The list includes newly approved therapies as well as additional indications for ex...